Report for Lanctot KL

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (25)

Title : Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial - Lanctot_2023_Am.J.Geriatr.Psychiatry__
Author(s) : Lanctot KL , Rivet L , Tumati S , Perin J , Sankhe K , Vieira D , Mintzer J , Rosenberg PB , Shade D , Lerner AJ , Padala PR , Brawman-Mintzer O , van Dyck CH , Porsteinsson AP , Craft S , Levey AI , Padala KP , Herrmann N
Ref : American Journal of Geriatry & Psychiatry , : , 2023
Abstract : Lanctot_2023_Am.J.Geriatr.Psychiatry__
ESTHER : Lanctot_2023_Am.J.Geriatr.Psychiatry__
PubMedSearch : Lanctot_2023_Am.J.Geriatr.Psychiatry__
PubMedID: 37385898

Title : Cytochrome p450-soluble epoxide hydrolase derived linoleic acid oxylipins and cognitive performance in type 2 diabetes - Anita_2023_J.Lipid.Res__100395
Author(s) : Anita NZ , Kwan F , Ryoo SW , Major-Orfao C , Lin WZ , Noor S , Lanctot KL , Herrmann N , Oh PI , Shah BR , Gilbert J , Assal A , Halperin IJ , Taha AY , Swardfager W
Ref : J Lipid Res , :100395 , 2023
Abstract : Anita_2023_J.Lipid.Res__100395
ESTHER : Anita_2023_J.Lipid.Res__100395
PubMedSearch : Anita_2023_J.Lipid.Res__100395
PubMedID: 37245563

Title : Soluble Epoxide Hydrolase Derived Linoleic Acid Oxylipins, Small Vessel Disease Markers, and Neurodegeneration in Stroke - Yu_2023_J.Am.Heart.Assoc_12_e026901
Author(s) : Yu D , Liang N , Zebarth J , Shen Q , Ozzoude M , Goubran M , Rabin JS , Ramirez J , Scott CJM , Gao F , Bartha R , Symons S , Haddad SMH , Berezuk C , Tan B , Kwan D , Hegele RA , Dilliott AA , Nanayakkara ND , Binns MA , Beaton D , Arnott SR , Lawrence-Dewar JM , Hassan A , Dowlatshahi D , Mandzia J , Sahlas D , Casaubon L , Saposnik G , Otoki Y , Lanctot KL , Masellis M , Black SE , Swartz RH , Taha AY , Swardfager W
Ref : J Am Heart Assoc , 12 :e026901 , 2023
Abstract : Yu_2023_J.Am.Heart.Assoc_12_e026901
ESTHER : Yu_2023_J.Am.Heart.Assoc_12_e026901
PubMedSearch : Yu_2023_J.Am.Heart.Assoc_12_e026901
PubMedID: 36583428

Title : Pharmacological Management of Apathy in Dementia - Azhar_2022_CNS.Drugs__
Author(s) : Azhar L , Kusumo RW , Marotta G , Lanctot KL , Herrmann N
Ref : CNS Drugs , : , 2022
Abstract : Azhar_2022_CNS.Drugs__
ESTHER : Azhar_2022_CNS.Drugs__
PubMedSearch : Azhar_2022_CNS.Drugs__
PubMedID: 35006557

Title : Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes - Anita_2021_Psychoneuroendocrinology_126_105149
Author(s) : Anita NZ , Forkan N , Kamal R , Nguyen MM , Yu D , Major-Orfao C , Wong SK , Lanctot KL , Herrmann N , Oh PI , Shah BR , Gilbert J , Assal A , Halperin IJ , Pedersen TL , Taha AY , Swardfager W
Ref : Psychoneuroendocrinology , 126 :105149 , 2021
Abstract : Anita_2021_Psychoneuroendocrinology_126_105149
ESTHER : Anita_2021_Psychoneuroendocrinology_126_105149
PubMedSearch : Anita_2021_Psychoneuroendocrinology_126_105149
PubMedID: 33503568

Title : Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia - Ahmed_2019_Drugs.Aging_36_589
Author(s) : Ahmed M , Malik M , Teselink J , Lanctot KL , Herrmann N
Ref : Drugs & Aging , 36 :589 , 2019
Abstract : Ahmed_2019_Drugs.Aging_36_589
ESTHER : Ahmed_2019_Drugs.Aging_36_589
PubMedSearch : Ahmed_2019_Drugs.Aging_36_589
PubMedID: 30957198

Title : Pharmacological interventions for apathy in Alzheimer's disease - Ruthirakuhan_2018_Cochrane.Database.Syst.Rev_5_CD012197
Author(s) : Ruthirakuhan MT , Herrmann N , Abraham EH , Chan S , Lanctot KL
Ref : Cochrane Database Syst Rev , 5 :CD012197 , 2018
Abstract : Ruthirakuhan_2018_Cochrane.Database.Syst.Rev_5_CD012197
ESTHER : Ruthirakuhan_2018_Cochrane.Database.Syst.Rev_5_CD012197
PubMedSearch : Ruthirakuhan_2018_Cochrane.Database.Syst.Rev_5_CD012197
PubMedID: 29727467

Title : A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease - Herrmann_2016_J.Am.Med.Dir.Assoc_17_142
Author(s) : Herrmann N , O'Regan J , Ruthirakuhan M , Kiss A , Eryavec G , Williams E , Lanctot KL
Ref : J Am Med Dir Assoc , 17 :142 , 2016
Abstract : Herrmann_2016_J.Am.Med.Dir.Assoc_17_142
ESTHER : Herrmann_2016_J.Am.Med.Dir.Assoc_17_142
PubMedSearch : Herrmann_2016_J.Am.Med.Dir.Assoc_17_142
PubMedID: 26482056

Title : Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments - Liu_2016_Curr.Alzheimer.Res_13_1134
Author(s) : Liu CS , Ruthirakuhan M , Chau SA , Herrmann N , Carvalho AF , Lanctot KL
Ref : Curr Alzheimer Res , 13 :1134 , 2016
Abstract : Liu_2016_Curr.Alzheimer.Res_13_1134
ESTHER : Liu_2016_Curr.Alzheimer.Res_13_1134
PubMedSearch : Liu_2016_Curr.Alzheimer.Res_13_1134
PubMedID: 27137221

Title : Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease - Ruthirakuhan_2016_Expert.Opin.Pharmacother_17_2417
Author(s) : Ruthirakuhan M , Herrmann N , Suridjan I , Abraham EH , Farber I , Lanctot KL
Ref : Expert Opin Pharmacother , 17 :2417 , 2016
Abstract : Ruthirakuhan_2016_Expert.Opin.Pharmacother_17_2417
ESTHER : Ruthirakuhan_2016_Expert.Opin.Pharmacother_17_2417
PubMedSearch : Ruthirakuhan_2016_Expert.Opin.Pharmacother_17_2417
PubMedID: 27825018

Title : Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials - O'Regan_2015_J.Clin.Psychiatry_76_e1424
Author(s) : O'Regan J , Lanctot KL , Mazereeuw G , Herrmann N
Ref : J Clin Psychiatry , 76 :e1424 , 2015
Abstract : O'Regan_2015_J.Clin.Psychiatry_76_e1424
ESTHER : O'Regan_2015_J.Clin.Psychiatry_76_e1424
PubMedSearch : O'Regan_2015_J.Clin.Psychiatry_76_e1424
PubMedID: 26646039

Title : Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study - Behl_2014_Alzheimers.Res.Ther_6_48
Author(s) : Behl P , Edwards JD , Kiss A , Lanctot KL , Streiner DL , Black SE , Stuss DT
Ref : Alzheimers Res Ther , 6 :48 , 2014
Abstract : Behl_2014_Alzheimers.Res.Ther_6_48
ESTHER : Behl_2014_Alzheimers.Res.Ther_6_48
PubMedSearch : Behl_2014_Alzheimers.Res.Ther_6_48
PubMedID: 25484926

Title : Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012 - Herrmann_2013_Alzheimers.Res.Ther_5_S5
Author(s) : Herrmann N , Lanctot KL , Hogan DB
Ref : Alzheimers Res Ther , 5 :S5 , 2013
Abstract : Herrmann_2013_Alzheimers.Res.Ther_5_S5
ESTHER : Herrmann_2013_Alzheimers.Res.Ther_5_S5
PubMedSearch : Herrmann_2013_Alzheimers.Res.Ther_5_S5
PubMedID: 24565367

Title : Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? - Levy_2012_Drugs.Aging_29_167
Author(s) : Levy K , Lanctot KL , Farber SB , Li A , Herrmann N
Ref : Drugs & Aging , 29 :167 , 2012
Abstract : Levy_2012_Drugs.Aging_29_167
ESTHER : Levy_2012_Drugs.Aging_29_167
PubMedSearch : Levy_2012_Drugs.Aging_29_167
PubMedID: 22350526

Title : Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type - Pinto_2011_Ageing.Res.Rev_10_404
Author(s) : Pinto T , Lanctot KL , Herrmann N
Ref : Ageing Res Rev , 10 :404 , 2011
Abstract : Pinto_2011_Ageing.Res.Rev_10_404
ESTHER : Pinto_2011_Ageing.Res.Rev_10_404
PubMedSearch : Pinto_2011_Ageing.Res.Rev_10_404
PubMedID: 21292041

Title : Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts - Herrmann_2011_Int.Psychogeriatr_23_539
Author(s) : Herrmann N , Black SE , Li A , Lanctot KL
Ref : Int Psychogeriatr , 23 :539 , 2011
Abstract : Herrmann_2011_Int.Psychogeriatr_23_539
ESTHER : Herrmann_2011_Int.Psychogeriatr_23_539
PubMedSearch : Herrmann_2011_Int.Psychogeriatr_23_539
PubMedID: 20849673

Title : The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort - Behl_2008_Int.Psychogeriatr_20_1141
Author(s) : Behl P , Lanctot KL , Streiner DL , Black SE
Ref : Int Psychogeriatr , 20 :1141 , 2008
Abstract : Behl_2008_Int.Psychogeriatr_20_1141
ESTHER : Behl_2008_Int.Psychogeriatr_20_1141
PubMedSearch : Behl_2008_Int.Psychogeriatr_20_1141
PubMedID: 18606043

Title : Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients - Behl_2007_Arch.Neurol_64_266
Author(s) : Behl P , Bocti C , Swartz RH , Gao F , Sahlas DJ , Lanctot KL , Streiner DL , Black SE
Ref : Archives of Neurology , 64 :266 , 2007
Abstract : Behl_2007_Arch.Neurol_64_266
ESTHER : Behl_2007_Arch.Neurol_64_266
PubMedSearch : Behl_2007_Arch.Neurol_64_266
PubMedID: 17296844

Title : Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease - Herrmann_2007_Can.J.Psychiatry_52_630
Author(s) : Herrmann N , Lanctot KL
Ref : Can J Psychiatry , 52 :630 , 2007
Abstract : Herrmann_2007_Can.J.Psychiatry_52_630
ESTHER : Herrmann_2007_Can.J.Psychiatry_52_630
PubMedSearch : Herrmann_2007_Can.J.Psychiatry_52_630
PubMedID: 18020111

Title : Cholinesterase inhibitors slow decline in executive functions, rather than memory, in Alzheimer's disease: a 1-year observational study in the Sunnybrook dementia cohort - Behl_2006_Curr.Alzheimer.Res_3_147
Author(s) : Behl P , Lanctot KL , Streiner DL , Guimont I , Black SE
Ref : Curr Alzheimer Res , 3 :147 , 2006
Abstract : Behl_2006_Curr.Alzheimer.Res_3_147
ESTHER : Behl_2006_Curr.Alzheimer.Res_3_147
PubMedSearch : Behl_2006_Curr.Alzheimer.Res_3_147
PubMedID: 16611015

Title : The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease - Thompson_2004_Expert.Opin.Drug.Saf_3_425
Author(s) : Thompson S , Lanctot KL , Herrmann N
Ref : Expert Opin Drug Safety , 3 :425 , 2004
Abstract : Thompson_2004_Expert.Opin.Drug.Saf_3_425
ESTHER : Thompson_2004_Expert.Opin.Drug.Saf_3_425
PubMedSearch : Thompson_2004_Expert.Opin.Drug.Saf_3_425
PubMedID: 15335298

Title : The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach - Wu_2003_CNS.Drugs_17_1045
Author(s) : Wu G , Lanctot KL , Herrmann N , Moosa S , Oh PI
Ref : CNS Drugs , 17 :1045 , 2003
Abstract : Wu_2003_CNS.Drugs_17_1045
ESTHER : Wu_2003_CNS.Drugs_17_1045
PubMedSearch : Wu_2003_CNS.Drugs_17_1045
PubMedID: 14594444

Title : Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease - Lanctot_2003_J.Psychiatry.Neurosci_28_13
Author(s) : Lanctot KL , Herrmann N , LouLou MM
Ref : J Psychiatry Neurosci , 28 :13 , 2003
Abstract : Lanctot_2003_J.Psychiatry.Neurosci_28_13
ESTHER : Lanctot_2003_J.Psychiatry.Neurosci_28_13
PubMedSearch : Lanctot_2003_J.Psychiatry.Neurosci_28_13
PubMedID: 12587847

Title : Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis - Lanctot_2003_CMAJ_169_557
Author(s) : Lanctot KL , Herrmann N , Yau KK , Khan LR , Liu BA , LouLou MM , Einarson TR
Ref : Cmaj , 169 :557 , 2003
Abstract : Lanctot_2003_CMAJ_169_557
ESTHER : Lanctot_2003_CMAJ_169_557
PubMedSearch : Lanctot_2003_CMAJ_169_557
PubMedID: 12975222

Title : Donepezil for behavioural disorders associated with Lewy bodies: a case series - Lanctot_2000_Int.J.Geriatr.Psychiatry_15_338
Author(s) : Lanctot KL , Herrmann N
Ref : Int J Geriatr Psychiatry , 15 :338 , 2000
Abstract : Lanctot_2000_Int.J.Geriatr.Psychiatry_15_338
ESTHER : Lanctot_2000_Int.J.Geriatr.Psychiatry_15_338
PubMedSearch : Lanctot_2000_Int.J.Geriatr.Psychiatry_15_338
PubMedID: 10767734